In This Article:
Nikos Pekiaridis / NurPhoto via Getty Images
Key Takeaways
-
Gilead Sciences missed first-quarter revenue estimates as sales of its COVID-19 and cancer drugs declined.
-
The biopharma's profit got a lift from higher prices and demand for its HIV treatments.
-
Gilead Sciences reduced its full-year profit outlook.
Gilead Sciences (GILD) shares fell Friday, a day after the biopharmaceutical firm reported weak sales of its COVID-19 and cancer treatments, and cut its full-year profit guidance.
The company's first-quarter revenue slipped 0.3% year-over-year to $6.67 billion, while analysts surveyed by Visible Alpha were looking for $6.81 billion. Earnings per share (EPS) of $1.81 was better than expected.
Sales of its Veklury COVID-19 drug sank 45% to $302 million on "lower rates of COVID-19 related hospitalizations across regions." Sales of its breast cancer medicine, Trodelvy, declined 5% to $293 million on what the company called "inventory dynamics" and lower average price realization.
On the plus side, HIV product sales increased 6% to $4.6 billion, boosted by higher prices and demand. Its liver disease portfolio posted a 3% sales gain to $758 million.
The company reduced its 2025 EPS outlook to a range of $5.65 to $6.05, versus the previous $5.95 to $6.35.
Even with today's 4% slide, shares of Gilead Sciences remain up about 11% so far this year.
TradingView
Read the original article on Investopedia